While Leerink still expects Zoetis to post revenue and earnings growth, it sees the pace decelerating as rivals like Elanco and Merck (NSE: PROR) gain share. The firm forecasts Zoetis EPS growth to ...

Joe Spector, founder of Dutch and Hims & Hers co-founder, joins us to discuss how telehealth is transforming pet care—and ...

The industry has long boasted healthy and steady growth rates. Critically, Zoetis also boasts high and improving levels of profitability.

Real change takes a long time, and when it happens, it must be recognized. The FDA and the NIH have announced their move away ...